Values First Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Values First Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$228K	Buy	74,236 +2,043	+3%	+$7.89K	0.12%	155
2025 Q4	$295K	Sell	72,193 -17,022	-19%	-$84.3K	0.15%	139
2025 Q3	$435K	Sell	89,215 -1,759	-2%	-$9.24K	0.23%	114
2025 Q2	$460K	Buy	90,974 +1,011	+1%	+$4.97K	0.25%	111
2025 Q1	$481K	Buy	89,963 +188	+0.2%	+$1.37K	0.28%	100
2024 Q4	$607K	Buy	89,775 +29,552	+49%	+$199K	0.33%	82
2024 Q3	$397K	Sell	60,223 -1,540	-2%	-$11K	0.22%	108
2024 Q2	$463K	Sell	61,763 -370	-0.6%	-$3.23K	0.28%	90
2024 Q1	$619K	Buy	62,133 +2,928	+5%	+$32.6K	0.36%	77
2023 Q4	$584K	Buy	59,205 +6,140	+12%	+$43.8K	0.35%	87
2023 Q3	$406K	Sell	53,065 -361	-0.7%	-$3.6K	0.26%	106
2023 Q2	$399K	Buy	53,426 +23,137	+76%	+$162K	0.24%	109
2023 Q1	$202K	Buy	+30,289	New	+$240K	0.13%	137

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Values First Advisors's RXRX Position: Q1 2026 in Review

Values First Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 2.8% in Q1 2026, buying an estimated $7.89K and bringing the position to 74,236 shares worth $228K. The position accounts for 0.12% of the portfolio, ranked #155.

Values First Advisors first reported a position in RXRX in Q1 2023 and has held it in 13 quarters since. The position peaked at $619K in Q1 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Values First Advisors held 74,236 shares of Recursion Pharmaceuticals worth $228K as of Q1 2026.
Values First Advisors bought 2,043 Recursion Pharmaceuticals shares in Q1 2026, an estimated $7.89K.
Recursion Pharmaceuticals made up 0.12% of Values First Advisors's portfolio in Q1 2026, its #155 holding.
Values First Advisors first reported a position in Recursion Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
Values First Advisors's Recursion Pharmaceuticals position peaked at $619K in Q1 2024.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Values First Advisors's 13F filing for Q1 2026, filed 17 Apr 2026.